Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
15.6M
-
Shares change
-
+2.72M
-
Total reported value, excl. options
-
$251M
-
Value change
-
+$43.7M
-
Number of buys
-
33
-
Number of sells
-
-8
-
Price
-
$16.09
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q2 2017
49 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q2 2017.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.6M shares
of 28M outstanding shares and own 55.69% of the company stock.
Largest 10 shareholders include Flagship Pioneering Inc. (4.81M shares), FMR LLC (3.93M shares), DEERFIELD MANAGEMENT CO (1.27M shares), WELLINGTON MANAGEMENT GROUP LLP (995K shares), Redmile Group, LLC (973K shares), BAKER BROS. ADVISORS LP (575K shares), BlackRock Inc. (545K shares), Aisling Capital LLC (509K shares), VANGUARD GROUP INC (383K shares), and Cormorant Asset Management, LLC (296K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.